Cover Image
市場調查報告書

亞太地區氣喘治療藥市場:∼2021年

Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns

出版商 GBI Research 商品編碼 355738
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區氣喘治療藥市場:∼2021年 Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns
出版日期: 2016年03月01日 內容資訊: 英文 130 Pages
簡介

氣喘,是特徵為呼吸急促和喘鳴的呼吸道慢性發炎性疾病,依據患者而發病頻率和重度不相同。氣喘治療有長期的控制和迅速緩和法。2014∼2021年,預計亞太地區的氣喘治療藥市場以年複合成長率7.2%擴大,達到56億美元。

本報告提供亞太地區氣喘治療藥市場相關調查,氣喘的概要與治療方法,現有的治療藥與新治療藥的競爭趨勢,至2021年的市場擴大預測等彙整資料。

第1章 目錄

第2章 簡介

  • 疾病的簡介
  • 流行病學
  • 症狀
  • 病因與病理學
  • 診斷
  • 分類
  • 治療指南和治療方法
    • 氣喘維持治療的ICS單劑療法
    • 第一次維持療法的Montelukast sodium
    • ICS/LABA聯合治療
    • 附加元件治療

第3章 已上市產品

  • 概要
  • 氣喘維持療法的ICS
  • 氣喘維持療法的ICS/LABA聯合治療
  • 氣喘維持療法的ICS或ICS/LABA聯合治療的並用治療
  • 已上市產品的有效性和安全性比較

第4章 開發平台分析

  • 概要
  • 各開發階段、分子類型、給藥途徑、計劃類型開發平台
  • 各分子標的開發平台
  • 有前途的開發平台候補
  • 開發中產品的有效性及安全性比較

第5章 臨床實驗分析

  • 失敗率
  • 臨床實驗的規模
  • 臨床實驗期間
  • 臨床實驗方法的摘要

第6章 多方案預測

  • 各地區市場
  • 亞太地區市場
  • 印度
  • 中國
  • 澳洲
  • 韓國
  • 日本

第7章 促進要素與阻礙

  • 促進要素
    • 罹患率的上升
    • 費用的價格市場進入
    • 治療的選項擴大
  • 障礙
    • 傳統醫藥品的使用
    • 對治療計劃的堅持
    • 原因的理解的限制
    • 認知度不足與生技藥品的價格高

第8章 交易與策略性聯盟

  • 競爭開發
  • 授權

第9章 附錄

圖表

目錄
Product Code: GBIHC403MR

Executive Summary

Asthma is a common chronic inflammatory disease of the airways, characterized by recurrent attacks of breathlessness and wheezing, which vary in frequency and severity from patient to patient. The exact causes of asthma are currently unknown, and may be the result of a combination of factors, although two major factors thought to be involved are environmental exposure and host factors, particularly genes.

Asthma treatment can be classed as either a long-term control medication, aimed at controlling persistent asthma, or a quick-relief medication, for the relief of exacerbations and acute symptoms. Long-term control medication includes Inhaled Corticosteroids (ICS), immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and methylxanthines. In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be used in combination with ICSs – but not as monotherapies – for moderate or severe persistent asthma. Currently, only one biologic – Xolair (omalizumab) – is approved as an add-on therapy for the treatment of allergic asthma in the Asia-Pacific region.  Nevertheless, significant unmet need remains for the treatment of severe eosinophilic asthma.

Scope

The current asthma market in the Asia-Pacific region contains novel products, including Xolair, a recombinant humanized monoclonal anti-IgE antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo, an ICS-LABA combination therapy, and Spiriva, a LAMA.

What are the competitive advantages of the existing novel drugs?

With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.

Which classes of novel drugs are most prominent within the pipeline?

Is there strong potential for the pipeline to address unmet needs within the asthma market - specifically for severe eosinophilic asthma?

Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.

How do failure rates vary by product stage of development, molecule type, and mechanism of action?

How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014-2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.

Which markets make the most significant contribution to the current market size?

What are the epidemiology trends in these markets?

Will new market entrants lead to substantial changes in annual therapy costs?

How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?

Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.

Will affordability threaten the commercial success of existing drugs as well as newer biologics?

Which of the assessed countries have affordability concerns?

Reasons to buy

This report will enable you to -

  • Understand the clinical context of asthma by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in asthma clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in asthma by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, South Korea and Japan.
  • Discover trends in licensing and co-development deals concerning asthma products and identify the major strategic consolidations that have shaped the commercial landscape.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology and Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Classification
  • 2.7. Treatment Guidelines and Options
    • 2.7.1. ICS Monotherapy for the Maintenance Treatment of Asthma
    • 2.7.2. Montelukast sodium as First-Line Maintenance Therapy
    • 2.7.3. ICS/LABA Combination Therapy
    • 2.7.4. Add-on Therapies

3. Marketed Products

  • 3.1. Overview
  • 3.2. ICS for the Maintenance Treatment of Asthma
    • 3.2.1. Arnuity (fluticasone furoate)
  • 3.3. ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
    • 3.3.1. Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) - GlaxoSmithKline
    • 3.3.2. Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-Promotion with Astellas Pharma
    • 3.3.3. Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline
    • 3.3.4. Flutiform (fluticasone propionate and formoterol fumarate) - SkyePharma
  • 3.4. Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
    • 3.4.1. Xolair (omalizumab) - Novartis and Genentech
    • 3.4.2. Montelukast sodium
    • 3.4.3. Spiriva (tiotropium bromide) - Boehringer Ingelheim
  • 3.5. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Analysis

  • 4.1. Overview
  • 4.2. Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 4.3. Pipeline by Molecular Target
  • 4.4. Promising Pipeline Molecules
    • 4.4.1. Mepolizumab - GlaxoSmithKline
    • 4.4.2. Reslizumab - Teva Pharmaceutical
    • 4.4.3. Lebrikizumab - Roche/Genentech
    • 4.4.4. Dupilumab - Regeneron Pharmaceuticals in Collaboration with Sanofi
    • 4.4.5. Tralokinumab - AstraZeneca
    • 4.4.6. Benralizumab - AstraZeneca
  • 4.5. Comparative Efficacy and Safety of Pipeline Products

5. Clinical Trial Analysis

  • 5.1. Failure Rate
    • 5.1.1. Overall Failure Rate
    • 5.1.2. Failure Rate by Phase and Molecule Type
    • 5.1.3. Failure Rate by Phase and Molecular Target
  • 5.2. Clinical Trial Size
    • 5.2.1. Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target
    • 5.2.2. Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target
  • 5.3. Clinical Trial Duration
    • 5.3.1. Trial Duration by Stage of Development by Molecule Type and Molecular Target
  • 5.4. Summary of Clinical Trial Metrics

6. Multi-Scenario Forecast

  • 6.1. Geographical Markets
  • 6.2. Asia-Pacific Market
  • 6.3. India
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. China
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Australia
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. South Korea
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size
  • 6.7. Japan
    • 6.7.1. Treatment Usage Patterns
    • 6.7.2. Annual Cost of Therapy
    • 6.7.3. Market Size

7. Drivers and Barriers

  • 7.1. Drivers
    • 7.1.1. Rising Prevalence
    • 7.1.2. New Costly Market Entries
    • 7.1.3. Growing Alternative Therapeutic Choices
  • 7.2. Barriers
    • 7.2.1. Usage of Traditional Medicines
    • 7.2.2. Treatment Regimen Adherence
    • 7.2.3. Limited Understanding of Underlying Causes
    • 7.2.4. Lack of Awareness and Affordability of High-Cost Biological Products

8. Deals and Strategic Consolidations

  • 8.1. Co-development Deals
    • 8.1.1. Deals by Region and Value
    • 8.1.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.1.3. Deal Value by Stage of Development, Molecule Type and Molecular Target
    • 8.1.4. Key Co-Development Deals
  • 8.2. Licensing Deals
    • 8.2.1. Deals by Region and Value
    • 8.2.2. Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
    • 8.2.3. Deal Value by Stage of Development, Molecule Type and Molecular Target
    • 8.2.4. Key Licensing Deals

9. Appendix

  • 9.1. All Pipeline Drugs by Phase of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. Phase I
    • 9.1.4. Phase II
    • 9.1.5. Phase III
    • 9.1.6. Pre-registration
  • 9.2. Summary of Multi-Scenario Market Forecasts to 2021
    • 9.2.1. Asia-Pacific
    • 9.2.2. China
    • 9.2.3. India
    • 9.2.4. Australia
    • 9.2.5. South Korea
    • 9.2.6. Japan
  • 9.3. References
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Product Competitiveness Framework
    • 9.5.6. Pipeline Analysis
    • 9.5.7. Forecasting Model
    • 9.5.8. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity According to GINA Guidelines (2002)
  • Table 2: Asthma Therapeutics, Global, Management of Chronic Asthma in Adults and Children above Five Years
  • Table 3: Asthma Diagnosis, Global, Symptoms and Management of Acute Asthma
  • Table 4: Asthma Trials, Global, Clinical Trial Endpoints
  • Table 5: Asthma Therapeutics, Global, All Pipeline Products, Discovery, 2015
  • Table 6: Asthma Therapeutics, Global, All Pipeline Products, Preclinical, 2015
  • Table 7: Asthma Therapeutics, Global, All Pipeline Products, Phase I, 2015
  • Table 8: Asthma Therapeutics, Global, All Pipeline Products, Phase II, 2015
  • Table 9: Asthma Therapeutics, Global, All Pipeline Products, Phase III, 2015
  • Table 10: Asthma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015
  • Table 11: Asthma Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021
  • Table 12: Asthma Therapeutics Market, China, Market Forecast, 2014-2021
  • Table 13: Asthma Therapeutics Market, India, Market Forecast, 2014-2021
  • Table 14: Asthma Therapeutics Market, Australia, Market Forecast, 2014-2021
  • Table 15: Asthma Therapeutics Market, South Korea, Market Forecast, 2014-2021
  • Table 16: Asthma Therapeutics Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: Asthma Therapeutics Market, Asia-Pacific, Heat Map for Marketed Products, 2015
  • Figure 2: Asthma Therapeutics Market, Asia-Pacific, Heat Map for Marketed Products (continued), 2015
  • Figure 3: Asthma Therapeutics Market, Global, Pipeline, 2015
  • Figure 4: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, 2015
  • Figure 5: Asthma Therapeutics Market, Asia-Pacific, Mepolizumab Forecast ($m), 2016-2021
  • Figure 6: Asthma Therapeutics Market, Asia-Pacific, Reslizumab Forecast ($m), 2016-2021
  • Figure 7: Asthma Therapeutics Market, Asia-pacific, Lebrikizumab Forecast ($m), 2018-2021
  • Figure 8: Asthma Therapeutics Market, Asia-Pacific, Dupilumab Forecast ($m), 2019-2021
  • Figure 9: Asthma Therapeutics Market, Asia-Pacific, Tralokinumab Forecast ($m), 2019-2021
  • Figure 10: Asthma Therapeutics Market, Asia-Pacific, Benralizumab Forecast ($m), 2020-2021
  • Figure 11: Asthma Therapeutics Market, Global, Heat Map for Pipeline Products, 2015
  • Figure 12: Asthma Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2015
  • Figure 13: Asthma Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2015
  • Figure 14: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2015
  • Figure 15: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2015
  • Figure 16: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2015
  • Figure 17: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006-2015
  • Figure 18: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecule Type, 2006-2015
  • Figure 19: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecular Target, 2006-2015
  • Figure 20: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2015
  • Figure 21: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006-2015
  • Figure 22: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 23: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 24: Asthma Therapeutics Market, Asia-Pacific, Treatment Patterns, 2014-2021
  • Figure 25: Asthma Therapeutics Market, Asia-Pacific, Market Size ($bn), 2014-2021
  • Figure 26: Asthma Therapeutics Market, India, Treatment Patterns, 2014-2021
  • Figure 27: Asthma Therapeutics Market, India, Annual Cost of Therapy ($), 2014-2021
  • Figure 28: Asthma Therapeutics Market, India, Market Size, 2014-2021
  • Figure 29: Asthma Therapeutics Market, China, Treatment Patterns, 2014-2021
  • Figure 30: Asthma Therapeutics Market, China, Annual Cost of Therapy ($), 2014-2021
  • Figure 31: Asthma Therapeutics Market, China, Market Size, 2014-2021
  • Figure 32: Asthma Therapeutics Market, Australia, Treatment Patterns, 2014-2021
  • Figure 33: Asthma Therapeutics Market, Australia, Annual Cost of Therapy ($), 2014-2021
  • Figure 34: Asthma Therapeutics Market, Australia, Market Size, 2014-2021
  • Figure 35: Asthma Therapeutics Market, South Korea, Treatment Patterns, 2014-2021
  • Figure 36: Asthma Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2014-2021
  • Figure 37: Asthma Therapeutics Market, South Korea, Market Size, 2014-2021
  • Figure 38: Asthma Therapeutics Market, Japan, Treatment Patterns, 2014-2021
  • Figure 39: Asthma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 40: Asthma Therapeutics Market, Japan, Market Size ($bn), 2014-2021
  • Figure 41: Asthma Therapeutics Market, Global, Co-Development Deals by Region, 2006-2015
  • Figure 42: Asthma Therapeutics Market, Global, Co-Development Deals by Value ($m), 2006-2015
  • Figure 43: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2015
  • Figure 44: Asthma Therapeutics Market, Global, Co-Development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
  • Figure 45: Asthma Therapeutics Market, Global, Co-Development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015
  • Figure 46: Asthma Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015
  • Figure 47: Asthma Therapeutics Market, Global, Licensing Deals by Region, 2006-2015
  • Figure 48: Asthma Therapeutics Market, Global, Licensing Deals by Value ($m), 2006-2015
  • Figure 49: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2015
  • Figure 50: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
  • Figure 51: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015
  • Figure 52: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015
Back to Top